NCT05268692 Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
| NCT ID | NCT05268692 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Kochi University |
| Condition | Pancreatic Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 500 participants in total. It began in 2019-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
Eligibility Criteria
Inclusion Criteria: elective pancreatectomy for pancreatic cancer Exclusion Criteria: a previous cancer surgery a body weight loss of \>10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.
Frequently Asked Questions
Who can join the NCT05268692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05268692 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05268692 currently recruiting?
Yes, NCT05268692 is actively recruiting participants. Visit ClinicalTrials.gov or contact Kochi University to inquire about joining.
Where is the NCT05268692 trial being conducted?
This trial is being conducted at Kochi, Japan.
Who is sponsoring the NCT05268692 clinical trial?
NCT05268692 is sponsored by Kochi University. The trial plans to enroll 500 participants.